title: Transmission of HCV to a chimpanzee using virus particles produced in an RNA-transfected HepG2 cell culture.
abstract: It was demonstrated previously that HepG2 cells produce negative strand RNA and virus-like particles after transfection with RNA transcribed from a full-length hepatitis C virus (HCV) cDNA clone [Dash et al. (1997) American Journal of Pathology, 151:363-373]. To determine in vivo infectivity of these in vitro synthesized viral particles, a chimpanzee was inoculated intravenously with HCV derived from HepG2 cells. The infected chimpanzee was examined serially for elevation of liver enzymes, for the presence of HCV RNA in the serum by reverse transcription nested polymerase chain reaction (RT-PCR), anti-HCV antibodies in the serum, and inflammation in the liver. The chimpanzee developed elevated levels of liver enzymes after the second week, but the levels fluctuated over a 10-week period. HCV RNA was detected in the serum of the chimpanzee at the second, seventh and ninth weeks after inoculation, and remained positive up to 25 weeks. Liver biopsies at Weeks 18 and 19 revealed of mild inflammation. Nucleotide sequence analysis of HCV recovered from the infected chimpanzee at the second and ninth weeks showed 100% sequence homology with the clone used for transfection studies. Serum anti-HCV antibodies were not detected by EIA during the 25 weeks follow-up period. These results suggest that intravenous administration of the virus-like particles derived from RNA-transfected HepG2 cells are infectious, and therefore, the pMO9.6-T7 clone is an infectious clone. These results provide new information that in vitro synthesized HCV particles produced from full-length HCV clone can cause infection in a chimpanzee. This study will facilitate the use of innovative approaches to the study of assembly of HCV particles and mechanisms of virus infectivity in cell culture.
authors.affiliation: Department of Pathology and Laboratory Medicine, Tulane University Health Science Center, New Orleans, Louisana 70112, USA. SDash@tulane.edu
authors.forename: S
authors.initials: S
authors.lastname: Dash
authors.forename: G
authors.initials: G
authors.lastname: Kalkeri
authors.forename: H M
authors.initials: HM
authors.lastname: McClure
authors.forename: R F
authors.initials: RF
authors.lastname: Garry
authors.forename: S
authors.initials: S
authors.lastname: Clejan
authors.forename: S N
authors.initials: SN
authors.lastname: Thung
authors.forename: K K
authors.initials: KK
authors.lastname: Murthy
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001483:Base Sequence; D001706:Biopsy; D004195:Disease Models, Animal; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification / Q000472:pathogenicity*; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000097:blood / Q000473:pathology / Q000821:virology*; D006801:Humans; D008099:Liver / Q000473:pathology; D008969:Molecular Sequence Data; D002679:Pan troglodytes; D012367:RNA, Viral / Q000097:blood / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016415:Sequence Alignment; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured; D014766:Viremia
chemical_list: D006508:Hepatitis Antibodies; D012367:RNA, Viral; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase